These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27102512)

  • 41. Stable coronary artery disease.
    Kallikazaros IE
    Hellenic J Cardiol; 2014; 55(2):175-7. PubMed ID: 24681799
    [No Abstract]   [Full Text] [Related]  

  • 42. The Impact of Ranolazine Treatment on Liver Tests in Patients With Coronary Artery Disease and Nonalcoholic Fatty Liver Disease.
    Imprialos KP; Stavropoulos K; Doumas M; Athyros VG
    Angiology; 2022 Jan; 73(1):5-6. PubMed ID: 33827290
    [No Abstract]   [Full Text] [Related]  

  • 43. Short Sleep Duration Is Associated With Abnormal Serum Aminotransferase Activities and Nonalcoholic Fatty Liver Disease.
    Kim D; Kim HJ; Kushida CA; Heo NY; Ahmed A; Kim WR
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):588-590. PubMed ID: 28882688
    [No Abstract]   [Full Text] [Related]  

  • 44. Metabolic syndrome and extension of coronary atherosclerosis.
    Yilmaz MB
    Int J Cardiol; 2007 May; 118(2):264; author reply 265-6. PubMed ID: 17011647
    [No Abstract]   [Full Text] [Related]  

  • 45. Nonalcoholic Fatty Liver Disease: Epidemiology, Natural History, and Diagnostic Challenges.
    Cholankeril G; Perumpail RB; Pham EA; Ahmed A; Harrison SA
    Hepatology; 2016 Sep; 64(3):954. PubMed ID: 27388553
    [No Abstract]   [Full Text] [Related]  

  • 46. Pigmentary disorders in ethnic skin.
    Halder RM; Nandedkar MA; Neal KW
    Dermatol Clin; 2003 Oct; 21(4):617-28, vii. PubMed ID: 14717403
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Letter to the Editor: Regional Epidemics of Nonalcoholic Fatty Liver Disease: Timing of Westernization and Ethnicity Matter.
    Huang JF; Dai CY; Yu ML; Chuang WL
    Hepatology; 2020 Aug; 72(2):781. PubMed ID: 31970797
    [No Abstract]   [Full Text] [Related]  

  • 48. Predicting Cardiovascular Health in Coronary Artery Risk Development in Young Adults.
    Gooding HC; Ning H; Gillman MW; Allen N; Goff DC; Rana JS; Chiuve S; Lloyd-Jones DM
    J Am Coll Cardiol; 2018 Jun; 71(22):2601-2602. PubMed ID: 29852983
    [No Abstract]   [Full Text] [Related]  

  • 49. Nonalcoholic Fatty Liver Disease and Coronary Artery Calcification.
    Stefan N
    Clin Gastroenterol Hepatol; 2016 Sep; 14(9):1345-6. PubMed ID: 27237428
    [No Abstract]   [Full Text] [Related]  

  • 50. 34th Bethesda Conference: Task force #3--What is the spectrum of current and emerging techniques for the noninvasive measurement of atherosclerosis?
    Redberg RF; Vogel RA; Criqui MH; Herrington DM; Lima JA; Roman MJ
    J Am Coll Cardiol; 2003 Jun; 41(11):1886-98. PubMed ID: 12798555
    [No Abstract]   [Full Text] [Related]  

  • 51. A Path Toward Improving Nonalcoholic Fatty Liver Disease Care Among Non-hepatologists.
    Liangpunsakul S
    Endocr Pract; 2022 May; 28(5):456-457. PubMed ID: 35569885
    [No Abstract]   [Full Text] [Related]  

  • 52. Adropin: Connection between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease.
    Erdol MA; Ertem S; Ertem AG; Demirtas K; Unal S; Karanfil M; Akdi A; Yayla C
    Med Princ Pract; 2020; 29(1):97. PubMed ID: 31291637
    [No Abstract]   [Full Text] [Related]  

  • 53. Reply to the Letter to the Editor "Adropin: Connection between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease".
    Kutlu O; Altun Ö; Dikker O; Aktaş Ş; Özsoy N; Arman Y; Özgün Çil E; Özcan M; Aydın Yoldemir Ş; Akarsu M; Toprak İD; Kırna K; Kutlu Y; Toprak Z; Eruzun H; Tükek T
    Med Princ Pract; 2020; 29(1):98. PubMed ID: 31505512
    [No Abstract]   [Full Text] [Related]  

  • 54. Clinical outcomes after coronary angiography in nonalcoholic fatty liver disease.
    Sarikaya S; Turan Y; Celikbilek M
    Hepatology; 2016 Nov; 64(5):1819-1820. PubMed ID: 27117944
    [No Abstract]   [Full Text] [Related]  

  • 55. MARC1 variant rs2642438 increases hepatic phosphatidylcholines and decreases severity of non-alcoholic fatty liver disease in humans.
    Luukkonen PK; Juuti A; Sammalkorpi H; Penttilä AK; Orešič M; Hyötyläinen T; Arola J; Orho-Melander M; Yki-Järvinen H
    J Hepatol; 2020 Sep; 73(3):725-726. PubMed ID: 32471727
    [No Abstract]   [Full Text] [Related]  

  • 56. 34th Bethesda Conference: Task force #4--How do we select patients for atherosclerosis imaging?
    Wilson PW; Smith SC; Blumenthal RS; Burke GL; Wong ND
    J Am Coll Cardiol; 2003 Jun; 41(11):1898-906. PubMed ID: 12798556
    [No Abstract]   [Full Text] [Related]  

  • 57. Non-alcoholic fatty liver disease and coronary atherosclerosis-does myocardial glucose metabolism provide the missing link?
    Clifford SM; Murphy DJ
    J Nucl Cardiol; 2021 Apr; 28(2):621-623. PubMed ID: 31201689
    [No Abstract]   [Full Text] [Related]  

  • 58. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.
    Jendle J; Grunberger G; Blevins T; Giorgino F; Hietpas RT; Botros FT
    Diabetes Metab Res Rev; 2016 Nov; 32(8):776-790. PubMed ID: 27102969
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity.
    Costa LJ; Hari PN; Kumar SK
    Leuk Lymphoma; 2016 Dec; 57(12):2827-2832. PubMed ID: 27104965
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Smoker's Paradox in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Gupta T; Kolte D; Khera S; Harikrishnan P; Mujib M; Aronow WS; Jain D; Ahmed A; Cooper HA; Frishman WH; Bhatt DL; Fonarow GC; Panza JA
    J Am Heart Assoc; 2016 Apr; 5(4):. PubMed ID: 27107131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.